Kilter Group’s AbbVie ABBV Stock Holding History

Kilter Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125K	Buy	498 +48	+11%	+$10.3K	0.05%	75
2026 Q1	$97.8K	Buy	450 +6	+1%	+$1.33K	0.04%	75
2025 Q4	$101K	Sell	444 -4	-0.9%	-$911	0.04%	75
2025 Q3	$104K	Buy	448 +31	+7%	+$6.31K	0.05%	72
2025 Q2	$77.3K	Buy	+417	New	+$77.5K	0.04%	77

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kilter Group's ABBV Position: Q2 2026 in Review

Kilter Group increased its AbbVie (ABBV) stake by 11% in Q2 2026, buying an estimated $10.3K and bringing the position to 498 shares worth $125K. The position accounts for 0.05% of the portfolio, ranked #75.

Kilter Group first reported a position in ABBV in Q2 2025 and has held it in 5 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Kilter Group held 498 shares of AbbVie worth $125K as of Q2 2026.
Kilter Group bought 48 AbbVie shares in Q2 2026, an estimated $10.3K.
AbbVie made up 0.05% of Kilter Group's portfolio in Q2 2026, its #75 holding.
Kilter Group first reported a position in AbbVie in Q2 2025 and has held it in 5 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kilter Group's 13F filing for Q2 2026, filed 11 Aug 2026.